Marguerite Koutsoukos

Author

Also Known As

Angelica Kottkamp, Barbara Metch, Brittany Sanchez, Jeffrey A. Henderson, Koutsoukos, Marguerite, M. Koutsoukos, Marguerite Koutsoukos

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (Belgium)Sanofi (United States)National Institute of Allergy and Infectious Diseases National Institutes of Health Sanofi (France)

About

Marguerite Koutsoukos is an author at GlaxoSmithKline (Belgium) specializing in medicine, immunology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	2.4K
2	Immunology	16	19	2.4K
3	Epidemiology	3	3	222
4	Allergy	2	2	1.1K
5	Cell Biology	1	1	12

Marguerite Koutsoukos

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Human Immunodeficiency Virus Type 1<i>env</i>Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies Ming Li, Feng Gao, John R. Mascola, Journal of Virology Vaccine-elicited Neutralizing AntibodiesStandardized AssessmentsImmunodeficienciesImmunologyImmunotherapy	2005	1.1K
Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys Dan H. Barouch, Galit Alter, Thomas Broge, Science VaccinationVaccine SafetyProtective EfficacyVaccine DevelopmentRhesus Monkeys	2015	290
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults Glenda Gray, Linda‐Gail Bekker, Fatima Laher, New England Journal of Medicine	2021	221
Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers Pierre Vandepapelière, Yves Horsmans, Philippe Moris, Vaccine VaccinationHealthy Adult VolunteersVaccine DevelopmentVaccine TargetImmunology	2008	220
Potent Induction of Focused Th1‐Type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a Recombinant<i>Plasmodium falciparum</i>Malaria Vaccine Ajit Lalvani, Phillipe Moris, Gérald Voss, The Journal of Infectious Diseases	1999	155
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study Paul A. Goepfert, Bo Fu, Anne-Laure Chabanon, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccinologyVaccine DevelopmentImmunology	2021	123
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial Linda‐Gail Bekker, Zoe Moodie, Nicole Grunenberg, The Lancet HIV	2018	121
The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans Kenneth Von Eschen, Royce A. Morrison, Madeleine Braun, Human Vaccines	2009	104
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers Paul A. Goepfert, Georgia D. Tomaras, Helen Horton, Vaccine VaccinationUninfected Human VolunteersVaccine DevelopmentT-cell ResponsesHuman Retrovirus	2006	92
Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations Wilton B. Williams, Jinsong Zhang, Chuancang Jiang, Nature Communications	2017	86

Page 1